Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK2141795 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Stage 1 | EXPERIMENTAL | Three to six patients on a medium dose of GSK2141795 for four weeks |
| Stage 2 | EXPERIMENTAL | Nine to eighteen subjects on a low, medium or high dose of GSK2141795 for four weeks |
| GSK2141795 | EXPERIMENTAL | Oral GSK214179 given daily to patients with cancer. Groups of approximately three patients will receive GSK2141795 at increasing doses until a maximum tolerated dose is identified. |
| Name | Type | Description |
|---|---|---|
| GSK2141795 | DRUG | GSK2141795 is an oral, low nanomolar pan-AKT kinase inhibitor that demonstrates activity in hematologic and solid tumor cell lines. It also delays tumor growth in a dose dependent manner in solid tumor xenograft mouse models |
Inclusion Criteria: 1. Capable of giving written informed consent 2. Females of non-childbearing potential, 18 years or older with ovarian cancer 3. Histologically or cytologically confirmed diagnosis of PET-positive recurrent or persistent ovarian cancer 4. Histologically or cytologically confirme...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
GSK2141795 is an investigational small molecule being studied for the treatment of cancer and solid tumours. It is an oral AKT inhibitor that has been evaluated in Phase 1 clinical trials. The drug is not approved and remains in clinical development.
GSK2141795 targets AKT, a protein involved in cell survival and growth pathways. By inhibiting AKT, the drug aims to interfere with cancer cell proliferation. This mechanism was studied in early-phase trials for cancer and solid tumours.
GSK2141795 is being developed by GSK plc, a global pharmaceutical company listed on the stock exchange under the ticker GSK. The company has conducted clinical trials to evaluate the drug's safety and efficacy in oncology.
GSK2141795 is in Phase 1 of clinical development. It has completed Phase 1 trials, but it is not approved by regulatory authorities. The drug is still investigational and has not progressed to later-stage trials.
GSK2141795 has been studied in two completed Phase 1 trials. NCT00920257 enrolled 77 participants with cancer in the United States and Canada. NCT01266954 enrolled 36 female participants with solid tumours in the United Kingdom, focusing on ovarian cancer.
Yes, GSK2141795 is an AKT inhibitor. It is an oral small molecule designed to block AKT activity. The drug has been investigated in early-phase clinical trials for cancer and solid tumours, though it is not yet approved.